{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-037675","form_type":"8-K","ticker":"HLF","cik":"0001180262","company_name":"HERBALIFE LTD.","filed_at":"2025-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.717830+00:00","generated_at":"2026-05-23T02:01:16.440011+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"confidence":"high","headline":"Herbalife Q1 net sales $1.2B (down 3.4% YoY), adjusted EBITDA $164.9M beats guidance","bullets":["Net sales $1.2B at midpoint of guidance; down 3.4% YoY but up 1.4% on constant-currency basis.","Net income $50.4M; adjusted net income $59.9M; diluted EPS $0.49, adjusted diluted EPS $0.59.","Adjusted EBITDA $164.9M exceeds guidance; margin up 260 bps vs Q1 '24; leverage ratio reduced to 3.0x.","Full-year 2025 guidance revised: net sales range narrowed, adjusted EBITDA raised, capex reduced.","Completed acquisitions of Pro2col Health and Pruvit Ventures; formed HBL Link Bioscience with 51% ownership."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-037675","json":"https://secwatch.observer/filing/0001213900-25-037675.json","markdown":"https://secwatch.observer/filing/0001213900-25-037675.md","text":"https://secwatch.observer/filing/0001213900-25-037675.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1180262/000121390025037675/0001213900-25-037675-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1180262/000121390025037675/ea0240048-8k_herbalife.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T02:01:16.440011+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}